other pocs , page-52

You guys are digging up irrelevant outdated events to maintain your fairytale.
Here is the present status of the trials.
Here is the correct status
"In February 2015, the company announced that, after a brief cessation, it had recommenced US clinical trials on its Troponin I point-of-care product. The clinical trial is running at 12, geographically diverse, trial sites across the USA and is currently recruiting just under 70 patients per week. Furthermore, the actual rate of myocardial infarctions is tracking slightly higher than expected. Consequently, the project remains on course to have data collection, subsequent adjudication and statistical analysis all completed during the month of July with FDA submission planned for August, 2015. The product continues to demonstrate the excellent clinical performance demonstrated in our European CE marking trials and in the independent clinical evaluation carried out at Hennepin County Medical Center, Minneapolis and published at AACC in July, 2014. Furthermore, European evaluations are well underway along with product registrations in a number of countries including both China and Brazil.
In relation to Meritas BNP, the company expects USA clinical trials to be completed in September, 2015 with FDA submission following immediately thereafter. Finally, data from an independent clinical evaluation of the Meritas BNP product, carried out by Dr. Apple at Hennepin County, has been accepted for publication at the AACC meeting in Atlanta on July 26, 2015. This data indicates excellent clinical performance characteristics for Meritas BNP."

http://www.marketwatch.com/story/tr...eps-174-cents-dividend-of-22-cents-2015-04-30

The reason they were temporarily suspended?
"The failure has now been positively identified as being attributable to a format change in a chemical raw material purchased from a third party supplier. This change caused instability in the product’s performance, which only became apparent over a period of time, the group said."
Philips have been putting their release date back continuously.
If they do make it to market, they will be behind the market and not in front.
Meaning that they will have to be very very good for hospitals and doctors to bother replacing the existing market leader.

Fantasy does not make reality.